Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Managing heart rhythm disorders in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular comorbidity presents treatment challenges.
• Selective beta-blockers (BBs) are suggested as a beneficial treatment option, supported by various studies.

Purpose of the Study:

• To compare the number of exacerbations in COPD patients treated with either verapamil and digoxin combination or BBs alone.
• To analyze these differences across various stages of COPD (GOLD II and GOLD III).

Main Methods:

• A 12-month follow-up study included 68 COPD patients.
• Patients were categorized into GOLD II (moderate) and GOLD III (severe) COPD stages.
• Treatment groups included verapamil and digoxin combination versus BBs alone.

Main Results:

• COPD exacerbations significantly increased in GOLD III compared to GOLD II patients, irrespective of treatment.
• In GOLD II COPD, BBs showed a trend towards fewer exacerbations than verapamil and digoxin (p=0.007).
• No significant difference in exacerbations was observed between treatments in GOLD III COPD patients (p=0.577).

Conclusions:

• Selective BBs are a preferable pharmacological choice for cardiovascular comorbidity in moderate (GOLD II) COPD patients.
• BBs demonstrated a potential benefit in reducing exacerbations in GOLD II COPD patients compared to verapamil and digoxin.